Monitoring and Managing the Adherence to Antiretroviral Therapy in Patients with Human Immunodeficiency Virus Infection
-
摘要: 高效抗反转录病毒治疗大大降低了人类免疫缺陷病毒(human immunodeficiency virus, HIV)感染者的病死率, 使HIV感染者可获得长期存活。服药依从性是实现病毒抑制、延缓疾病进展的关键因素之一。目前依从性的测量方法可分为间接和直接测量两种。影响依从性的因素大致可分为个体水平因素、药物治疗方案因素、人际关系问题和结构性问题4大类。可提高依从性的方法有:短消息提醒、指导治疗及制定计划、实时依从性监测和应用长效抗病毒药物制剂等。虽然已有较多相关依从性的研究, 获得可推广的行之有效的依从性监测及提高手段仍存在较大挑战。Abstract: Highly effective antiretroviral therapy (ART) can greatly reduce the fatality rate in patients with human immunodeficiency virus infection and enable them to achieve long-term survival. Medication adherence is one of the key factors to achieve viral suppression and delay disease progression. Current methods of measuring adherence can be divided into indirect and direct methods. The factors affecting adherence can be roughly divided into four categories:individual levels, drug treatment programs, interpersonal relationship problems, and structural problems. Strategies to improve adherence include short message alert, treatment guidance and planning, real-time adherence monitoring, and application of long-acting antiviral agents. Although there have been many studies on adherence, there are still major challenges in obtaining effective and scalable adherence monitoring and improvement tools.
-
Key words:
- human immunodeficiency virus /
- antiretroviral therapy /
- adherence
利益冲突 无 -
[1] Viswanathan S, Justice AC, Alexander GC, et al.Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy[J].J Acquir Immune Defic Syndr, 2015, 69:493-498. https://www.ncbi.nlm.nih.gov/pubmed/25886923 [2] Ghidei L, Simone M, Salow M, et al. Aging, antiretro-virals, and adherence:a meta analysis of adherence among older HIV-infected individuals[J].Drugs Aging, 2013, 30:809-819. [3] Kanters S, Park JJ, Chan K, et al.Interventions to improve adherence to antiretroviral therapy:a systematic review and network meta-analysis[J].Lancet HIV, 2017, 4:e31-e40. http://www.sciencedirect.com/science/article/pii/S2352301816302065 [4] Govindasamy D, Ford N, Kranzer K, et al. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care:a systematic review[J]. AIDS, 2012, 26:2059-2067. http://europepmc.org/abstract/MED/22781227 [5] Reuben RN, Spector AY, Mellins CA, et al.Optimizing ART adherence:update for HIV treatment and prevention[J].Curr HIV/AIDS Rep, 2014, 11:423-433. doi: 10.1007/s11904-014-0229-5 [6] Layer EH, Kennedy CE, Beckham SW, et al. Multi-level factors affecting entry into and engagement in the HIV continuum of care in Iringa, Tanzania[J].PLoS One, 2014, 9:e104961. http://europepmc.org/articles/PMC4138017 [7] Mudhune V, Gvetadze R, Girde S, et al.Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya[J].AIDS Behav, 2018, 22:918-928. doi: 10.1007/s10461-017-1724-7 [8] Carter A, de Pokomandy A, Loutfy M, et al. Validating a self-report measure of HIV viral suppression:an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study[J]. BMC Res Notes, 2017, 10:138. https://www.ncbi.nlm.nih.gov/pubmed/28340606 [9] Simoni JM, Kurth AE, Pearson CR, et al.Self-report measures of antiretroviral therapy adherence:A review with recommendations for HIV research and clinical management[J].AIDS Behav, 2006, 10:227-245. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=16783535 [10] Sewell J, Daskalopoulou M, Nakagawa F, et al. Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment[J]. HIV Med, 2017, 18:463-473. doi: 10.1111/hiv.12477/abstract [11] Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al.Assessing self-reported adherence to HIV therapy by questionnaire:the SERAD (Self-Reported Adherence) Study[J].AIDS Res Hum Retroviruses, 2007, 23:1166-1175. http://www.ncbi.nlm.nih.gov/pubmed/17961100/ [12] Shirazi TN, Summers AC, Smith BR, et al. Concordance Between Self-Report and Performance-Based Measures of Everyday Functioning in HIV-Associated Neurocognitive Disorders[J]. AIDS Behav, 2017, 21:2124-2134. http://europepmc.org/abstract/med/28108876 [13] Kagee A, Nel A.Assessing the association between self-report items for HIV pill adherence and biological measures[J].AIDS Care, 2012, 24:1448-1452. doi: 10.1080/09540121.2012.687816 [14] Garrison LE, Haberer JE.Technological methods to measure adherence to antiretroviral therapy and preexposure prophylaxis[J].Curr Opin HIV AIDS, 2017, 12:467-474. http://www.ncbi.nlm.nih.gov/pubmed/28590335 [15] Arnsten JH, Demas PA, Farzadegan H, et al.Antiretro-viral therapy adherence and viral suppression in HIV-infected drug users:Comparison of self-report and electronic monitoring[J]. Clin Infect Dis, 2001, 33:1417-1423. [16] Lampe FC.Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status[J]. AIDS, 2016, 30:1745-1759. https://discovery.ucl.ac.uk/id/eprint/1480007/1/Lampe_Sexual%20behaviour%20among%20people%20with%20HIV%20according%20to%20self-reported%20antiretroviral%20treatment%20and%20viral%20load%20status.pdf [17] San Lio MM, Carbini R, Germano P, et al.Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique[J]. Clin Infect Dis, 2008, 46:1609-1616. http://www.ncbi.nlm.nih.gov/pubmed/18419498 [18] Achieng L, Musangi H, Billingsley K, et al.The use of pill counts as a facilitator of adherence with antiretroviral therapy in resource limited settings[J].PLoS One, 2013, 8:e67259. http://www.ncbi.nlm.nih.gov/pubmed/24339861 [19] Raymond JF, Bucek A, Dolezal C, et al. Use of Unannounced Telephone Pill Counts to Measure Medication Adherence Among Adolescents and Young Adults Living With Perinatal HIV Infection[J].J Pediatr Psychol, 2017, 42:1006-1015. http://academic.oup.com/jpepsy/article/42/9/1006/3092230 [20] Okatch H, Beiter K, Eby J, et al.Brief Report:Apparent Antiretroviral Overadherence by Pill Count is Associated With HIV Treatment Failure in Adolescents[J].J Acquir Immune Defic Syndr, 2016, 72:542-545. http://smartsearch.nstl.gov.cn/paper_detail.html?id=c5a82541ee9166a71d32e7a85db69ff8 [21] Misdrahi D, Tessier A, Husky M, et al.Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS(R)):A six-month post-discharge prospective study[J].Schizophr Res, 2018, 193:114-118. https://www.ncbi.nlm.nih.gov/pubmed/28663027 [22] Wagner GJ. Does discontinuing the use of pill boxes to facilitate electronic monitoring impede adherence?[J]. Int J STD AIDS, 2003, 14:64-65. http://www.ncbi.nlm.nih.gov/pubmed/12590799 [23] Evans D, Berhanu R, Moyo F, et al.Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa[J].AIDS Behav, 2016, 20:2717-2728. https://www.ncbi.nlm.nih.gov/pubmed/27146828 [24] Baxi SM, Liu A, Bacchetti P, et al.Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures[J]. J Acquir Immune Defic Syndr, 2015, 68:13-20. doi: 10.1097/qai.0000000000000386 [25] Gandhi M, Ameli N, Bacchetti P, et al.Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy[J].Clin Infect Dis, 2011, 52:1267-1275. http://europepmc.org/articles/PMC3079399/ [26] Hendrix CW, Andrade A, Bumpus NN, et al.Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)[J].AIDS Res Hum Retroviruses, 2016, 32:32-43. [27] Hafezi H, Robertson TL, Au-Yeung K, et al.An inges-tible sensor for measuring medication adherence[J].IEEE Trans Biomed Eng, 2015, 62:99-109. http://www.ncbi.nlm.nih.gov/pubmed/25069107 [28] Chai PR, Castillo-Mancilla J, Buffkin E, et al.Utilizing an Ingestible Biosensor to Assess Real-Time Medication Adherence[J].J Med Toxicol, 2015, 11:439-444. doi: 10.1007/s13181-015-0494-8 [29] Mimiaga MJ, Bogart LM, Thurston IB, et al.Positive Strategies to Enhance Problem-Solving Skills (STEPS):A Pilot Randomized, Controlled Trial of a Multicomponent, Technology-Enhanced, Customizable Antiretroviral Adherence Intervention for HIV-Infected Adolescents and Young Adults[J]. AIDS Patient Care STDS, 2019, 33:21-24. http://www.ncbi.nlm.nih.gov/pubmed/30601059 [30] Bachman DeSilva M, Gifford AL, Keyi X, et al.Feasibi-lity and Acceptability of a Real-Time Adherence Device among HIV-Positive IDU Patients in China[J].AIDS Res Treat, 2013, 2013:957862. https://core.ac.uk/display/99253953 [31] Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al.Mobile phone technologies improve adherence to antiretro-viral treatment in a resource-limited setting:a randomized controlled trial of text message reminders[J].AIDS, 2011, 25:825-834. doi: 10.1097/QAD.0b013e32834380c1 [32] Duggal M, Chakrapani V, Liberti L, et al.Acceptability of Mobile Phone-Based Nurse-Delivered Counseling Intervention to Improve HIV Treatment Adherence and Self-Care Behaviors Among HIV-Positive Women in India[J].AIDS Patient Care STDS, 2018, 32:349-359. doi: 10.1089/apc.2017.0315 [33] Quintana Y, Gonzalez Martorell EA, Fahy D, et al.A Systematic Review on Promoting Adherence to Antiretroviral Therapy in HIV-infected Patients Using Mobile Phone Technology[J].Appl Clin Inform, 2018, 9:450-466. https://www.ncbi.nlm.nih.gov/pubmed/29925099 [34] Lyon ME, Trexler C, Akpan-Townsend C, et al.A family group approach to increasing adherence to therapy in HIV-infected youths:results of a pilot project[J].AIDS Patient Care STDS, 2003, 17:299-308. doi: 10.1089/108729103322108175 [35] Franke M, Murray M, Muñoz M, et al. Food insufficiency is a risk factor for suboptimal antiretroviral therapy adherence among HIV-infected adults in urban Peru[J]. AIDS Behav, 2011, 15:1483-1489. doi: 10.1007/s10461-010-9789-6 [36] Deribe K, Hailekiros F, Biadgilign S, et al. Defaulters from antiretroviral treatment in Jimma University Specialized Hospital, Southwest Ethiopia[J]. Trop Med Int Health, 2008, 13:328-333. doi: 10.1111/j.1365-3156.2008.02006.x [37] Martinez H, Palar K, Linnemayr S, et al.Tailored nutrition education and food assistance improve adherence to HIV antiretroviral therapy:evidence from Honduras[J].AIDS Behav, 2014, 18:S566-S577. doi: 10.1007/s10461-014-0786-z [38] Haberer JE, Kahane J, Kigozi I, et al.Real-time adher-ence monitoring for HIV antiretroviral therapy[J].AIDS Behav, 2010, 14:1340-1346. doi: 10.1007/s10461-010-9799-4 [39] de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, et al. Feasibility of real time medication monitoring among HIV infected and TB patients in a resource-limited setting[J]. AIDS Behav, 2016, 20:1097-1107. doi: 10.1007/s10461-015-1254-0 [40] Castillo-Mancilla JR, Haberer JE.Adherence Measurements in HIV:New Advancements in Pharmacologic Methods and Real-Time Monitoring[J]. Curr HIV/AIDS Rep, 2018, 15:49-59. doi: 10.1007/s11904-018-0377-0 [41] Stailey M, Conway SE, et al.Review of the Next Generation of Long-Acting Basal Insulins:Insulin Degludec and Insulin Glargine[J].Consult Pharm, 2017, 32:42-46. http://www.ncbi.nlm.nih.gov/pubmed/28077204 [42] McGowan I, Dezzutti CS, Siegel A, et al. Long-acting rilpivirine as potential preexposure prophylaxis for HIV-1 prevention (the MWRI-01 study):an openlabel, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment[J]. Lancet HIV, 2016, 3:e569-e578. doi: 10.1016/S2352-3018(16)30113-8 [43] Ferretti F, Boffito M.Rilpivirine long-acting for the prevention and treatment of HIV infection[J].Curr Opin HIV AIDS, 2018, 13:300-307. http://www.ncbi.nlm.nih.gov/pubmed/29794818
点击查看大图
计量
- 文章访问数: 304
- HTML全文浏览量: 17
- PDF下载量: 157
- 被引次数: 0